Clinical Trials Directory

Trials / Completed

CompletedNCT00792493

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Orion Corporation, Orion Pharma · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating multiple doses of ORM-12741 in healthy volunteers

Conditions

Interventions

TypeNameDescription
DRUGORM-12741Alternating panel multiple dose escalation

Timeline

Start date
2008-12-01
Primary completion
2009-06-01
Completion
2009-09-01
First posted
2008-11-18
Last updated
2009-09-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00792493. Inclusion in this directory is not an endorsement.

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741 (NCT00792493) · Clinical Trials Directory